Boundless Bio, Inc. Common Stock (BOLD) is a publicly traded Healthcare sector company. As of May 21, 2026, BOLD trades at $1.42 with a market cap of $31.90M and a P/E ratio of -0.55. BOLD moved +0.00% today. Year to date, BOLD is +20.34%; over the trailing twelve months it is -14.46%. Its 52-week range spans $0.96 to $3.75. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces BOLD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Boundless Bio Secures FDA IND for BBI-940, Opens KOMODO-1 Trial with $107.6M Runway: Boundless Bio’s FDA accepted its IND for BBI-940 and opened enrollment in the KOMODO-1 first-in-human trial targeting ER+/HER2- and TNBC-LAR breast cancers, aiming for proof-of-concept by mid-2028. The company ended 2025 with $107.6 million cash runway into late 2028 and reduced net loss to $58.2 million.
| Metric | Value |
|---|---|
| Price | $1.42 |
| Market Cap | $31.90M |
| P/E Ratio | -0.55 |
| EPS | $-2.60 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.75 |
| 52-Week Low | $0.96 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-58.20M |
| Gross Margin | 0.00% |
1 analysts cover BOLD: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.